Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (7430)	4/17/1999 7:59:00 AM
From: Epicenter	Read Replies (1) \| Respond to of 9523

I agree that PFE is making the right strategic move in continued heavy investing in R and D, particularly the D part. Very few, if any other pharma co., has the financial power and technical know-how to maximize future opportunities like PFE. (For example, WLA has the cash flow but not the "intelligence" (IMHO) to maximize R and D output). PFE could have easily stunted the increase of R and D spending and made the earnings look better. They didn't do that because that's the wrong way to operate this company. This is in such a great contrast to others who "fudge" the numbers to make the bottom line look good (I know, I've been an active participant in some of those exercises at a large pharma. The contrast between PFE and ALL other pharmas will become even greater when all of this R and D start to bear even more fruits. Epicenter